NCT05441475 2026-02-25
A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
Abbisko Therapeutics Co, Ltd
Phase 2 Enrolling by invitation
Abbisko Therapeutics Co, Ltd
Huabo Biopharm Co., Ltd.
Regeneron Pharmaceuticals
Taiho Oncology, Inc.
MeiraGTx UK II Ltd
Autolus Limited